Aehr Test Systems has emerged as a leveraged play on artificial intelligence infrastructure bottlenecks, with the stock rallying 400% year-to-date amid a strategic pivot from electric vehicle silicon carbide testing toward AI chip validation. The dominant narrative crystallized in mid-July when the company reported record bookings and projected revenue growth of 160-200% in fiscal 2027, triggering a 40% single-day surge on July 15. A $22 million follow-on production order announced August 12 reinforced sustained demand signals rather than one-time transactional dynamics. The shelf registration filing on July 28 sparked a temporary 5% pullback, signaling dilution concerns despite the company's capital-raising optionality. Macro tailwinds stem from hyperscaler data center capex acceleration and custom silicon proliferation across cloud providers. Sector momentum aligns with Teradyne and peer equipment suppliers benefiting from elevated chip fabrication intensity. The core risk centers on whether backlog conversion accelerates sufficiently to justify the expanded valuation multiple embedded in recent price action.